Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)
Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)
This study is designed to demonstrate that formoterol 12µg and 24µg delivered by a new
 inhalation device (Concept1) are equivalent to the corresponding dose of formoterol delivered
 by the Aerolizer device in terms of efficacy, in patients with persistent asthma.
Inclusion Criteria:

 -  History of asthma attacks

 -  Forced expiratory volume in 1 second (measure of how well the lungs are working) is
 greater than 60% of the predicted value

 Exclusion Criteria:

 -  Asthma is not stable: patients were admitted to hospital or received emergency room
 treatment

 -  Patients whose asthma drugs need changing within the month prior to the start of the
 study